Adrenomedullin
2002; Lippincott Williams & Wilkins; Volume: 90; Issue: 6 Linguagem: Inglês
10.1161/01.res.0000015462.11528.28
ISSN1524-4571
AutoresToshihiro Tsuruda, John C. Burnett,
Tópico(s)Hormonal Regulation and Hypertension
ResumoHomeCirculation ResearchVol. 90, No. 6Adrenomedullin Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBAdrenomedullinAn Autocrine/Paracrine Factor for Cardiorenal Protection Toshihiro Tsuruda and John C. BurnettJr Toshihiro TsurudaToshihiro Tsuruda From the Mayo Clinic, Rochester, Minn. and John C. BurnettJrJohn C. BurnettJr From the Mayo Clinic, Rochester, Minn. Originally published5 Apr 2002https://doi.org/10.1161/01.RES.0000015462.11528.28Circulation Research. 2002;90:625–627Since 1993, with the discovery of adrenomedullin (AM) by Kitamura and coworkers,1 we have gained many insights into the biology of this new peptide. Although AM was originally found in human pheochromocytoma, preproAM gene expression and its immunoreactivity are widely distributed in humans and rodents and found in cardiovascular tissues, kidney, digestive organs, nervous system, and tumor cells.2–4 While this ubiquitous AM distribution has prompted many investigators to clarify the role of AM, we advance the concept that the role of endogenous AM is especially important in cardiovascular and renal homeostasis. We now know that AM circulates in plasma and is present in organs and tissues with increases in AM activity in heart failure, hypertension, and renal dysfunction.5,6 Although AM synthesis may be mainly regulated by lipopolysaccharide (LPS) and cytokines, it has been reported that hormones, as well as physical stimuli, stimulate AM synthesis in smooth muscle cells (SMCs), endothelial cells (ECs), and cardiomyocytes.7–12 It is also accepted that AM has multiple functional properties linked to intracellular cyclic adenosine monophosphate (cAMP) elevation. Indeed, exogenous AM administration induces vasodilation and natriuresis with cAMP elevation, resulting in beneficial cardiorenal response in humans with heart failure.13 Although AM was originally found by monitoring cAMP elevation in platelets,1 supporting a key role for cAMP, it has been reported that the nitric oxide (NO)-cGMP pathway also contributes to actions of AM.14 In addition, a third pathway might mediate the AM signal.15AM as an Autocrine or Paracrine FactorTo date, the role of AM as an autocrine or paracrine factor has been studied using receptor antagonists, such as calcitonin gene-related peptide (CGRP), type 1 receptor antagonist [human CGRP (8-37)], the N-terminal-deleted form of AM [human AM (22-52)], and AM monoclonal antibodies for neutralizing AM biological activity.16–21 However, the effects of these former two antagonists to inhibit AM differ among studies, indicating the presence of AM receptor subtypes or differences of AM receptors in organ-specific or species-specific conditions. Several earlier studies have demonstrated the role of AM as an autocrine or paracrine factor but mainly in in vitro environments. The Figure illustrates the mechanistic action of AM as an autocrine or paracrine factor in the vasculature. For instance, Michibata et al20 have reported neutralization of endogenous AM by monoclonal antibodies' reduced basal production of cAMP and increased DNA synthesis in ECs. In addition, Kato et al21 have shown AM is antiapoptotic via a paracrine mechanism that can be neutralized by monoclonal antibody. These data indicate AM may act as a local factor as well as an endocrine factor. Download figureDownload PowerPointAutocrine and paracrine pathways for endogenous AM actions in the vasculature. Action of AM is mainly mediated by cAMP and NO-cGMP pathway. See text for details. AM indicates adrenomedullin; NOS, nitric oxide synthase; NO, nitric oxide; TNF-α, tumor necrosis factor-α; IL-1β, interleukin-1β; LPS, lipopolysaccharide; cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine monophosphate; PKG, protein kinase G; and PKA, protein kinase A.Lessons From Transgenic and Knockout MouseIn the present issue of Circulation Research, studies by Nishimatsu and coworkers22 have importantly demonstrated the protective properties of endogenous AM on renal injury, using transgenic and knockout mouse models. They concluded that AM has a cytoprotective property and that the beneficial "endogenous" effects of AM are mediated, in part, by the enhanced production of NO. This group has shown previously that in mice with AM overexpression, blood pressure was lower and there was resistance to LPS-induced hepatic injury and an increased mortality rate .23 On the other hand, AM gene knockout mice have also been established by two independent groups.24,25 In these studies, AM-deficient mice (heterozygous) had higher blood pressure compared with wild types and, importantly, homozygous mice were associated with death at midgestation and demonstrated cardiovascular abnormalities. From these gene engineering studies, endogenous AM clearly regulates blood pressure by controlling vascular tone and has cytoprotective properties that are in part mediated by an NO-cGMP pathway. These studies establish a critical role for endogenous AM in organogenesis. Further studies are warranted to clarify the role of endogenous AM, especially on the remodeling process in the cardiovascular system.Therapeutic Potential of Local AM in Cardiovascular and Renal DiseaseThe work by Nishimatsu et al22 supports the development of AM as a potential therapy in cardiorenal disease. McLatchie et al26 have isolated and cloned a receptor-modifying protein (RAMP) accessory protein that induces three isoforms (RAMP1, RAMP2, and RAMP3), and coexpression of RAMP2 or RAMP3 and calcitonin receptor-related receptor (CRLR) functions as a specific AM receptor. Kuwasako et al27 have recently defined the critical step for stimulating AM action inside RAMP2 and RAMP3. This finding indicates that development of receptor agonists or antagonists may modulate the action of endogenous AM and might be a useful means for treatment. Another therapeutic strategy comes from our understanding of modulating AM by degradation. To date, AM lacks oral activity and has a short plasma half-life so that intravenous infusions are required to achieve and maintain therapeutically effective levels. An emerging concept of treatment is to potentiate " endogenous" AM by inhibiting its degradation. AM is now thought to be a substrate for neutral endopeptidase (NEP), a membrane-bound zinc metalloprotease that is abundantly present in the kidney. Indeed, inhibition of NEP augments the natriuretic and diuretic action of AM in physiological conditions as well as in experimental heart failure.28,29 In addition, enhanced local production by AM gene delivery may be another strategy for treatment of cardiovascular and renal disease.As discussed, AM is present throughout the body and its action is mainly mediated by cAMP but also by cGMP elevation. When the AM molecule is given systemically, stimulation of intracellular cAMP and/or cGMP may result in many biological actions. Therefore, use of AM for modulating cardiorenal function may stimulate cellular activity in many organs. One concern is data reporting that AM promotes tumor growth via angiogenetic and antiapoptotic effects, resulting in possible carcinogenesis.4,30 The second issue is AM activation of NO. Nishimatsu and colleagues concluded that the beneficial effects of AM in renal protection might be secondary to NO release; however, as mentioned by Nishimatsu et al22 in this issue of Circulation Research, the role of NO in the cardiovascular system and kidney in pathological situations remains controversial. Whether low AM concentrations act as a beneficial factor may therefore critically depend on the magnitude of NO concentration in tissues. The last issue is that long-term effects of AM remain to be defined. Although low-dose administration of AM has been shown to have a beneficial effect and could be safe as short-term therapy in the treatment for congestive heart failure,13 extensive safety issues need to be addressed in long-term therapy strategies.SummaryIn summary, the study by Nishimatsu and coworkers advances our understanding of the biology of endogenous AM and supports the role of endogenous AM as an autocrine or paracrine factor in cardiorenal regulation. Furthermore, endogenous AM contributes a cytoprotective effect against organ damage, indicating that AM is a potential therapeutic candidate for the treatment of cardiovascular and renal disease.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.FootnotesCorrespondence to John C. Burnett, Jr, MD, Cardiorenal Research Laboratory, Mayo Clinic, 200 First St SW, Rochester, MN 55905. E-mail [email protected] References 1 Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, Eto T. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun. 1993; 192: 553–560.CrossrefMedlineGoogle Scholar2 Ichiki Y, Kitamura K, Kangawa K, Kawamoto M, Matsuo H, Eto T. Distribution and characterization of immunoreactive adrenomedullin in human tissue and plasma. FEBS Lett. 1994; 338: 6–10.CrossrefMedlineGoogle Scholar3 Sakata J, Shimokubo T, Kitamura K, Nakamura S, Kangawa K, Matsuo H, Eto T. Molecular cloning and biological activities of rat adrenomedullin, a hypotensive peptide. Biochem Biophys Res Commun. 1993; 195: 921–927.CrossrefMedlineGoogle Scholar4 Miller MJ, Martinez A, Unsworth EJ, Thiele CJ, Moody TW, Elsasser T, Cuttitta F. Adrenomedullin expression in human tumor cell lines: its potential role as an autocrine growth factor. J Biol Chem. 1996; 271: 23345–23351.CrossrefMedlineGoogle Scholar5 Jougasaki M, Wei C-M, McKinley LJ, Burnett JCJr. Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation. 1995; 92: 286–289.CrossrefMedlineGoogle Scholar6 Ishimitsu T, Nishikimi T, Saito Y, Kitamura K, Eto T, Kangawa K, Matsuo H, Omae T, Matsuoka H. Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest. 1994; 94: 2158–2561.CrossrefMedlineGoogle Scholar7 Isumi Y, Shoji H, Sugo S, Tochimoto T, Yoshioka M, Kangawa K, Matsuo H, Minamino N. Regulation of adrenomedullin production in rat endothelial cells. Endocrinology. 1998; 139: 838–846.CrossrefMedlineGoogle Scholar8 Sugo S, Minamino N, Shoji H, Kangawa K, Kitamura K, Eto T, Matsuo H. Production and secretion of adrenomedullin from vascular smooth muscle cells: augmented production by tumor necrosis factor-α. Biochem Biophys Res Commun. 1994; 203: 719–726.CrossrefMedlineGoogle Scholar9 Sugo S, Minamino N, Shoji H, Kangawa K, Matsuo H. Effects of vasoactive substances and cAMP related compounds on adrenomedullin production in cultured vascular smooth muscle cells. FEBS Lett. 1995; 369: 311–314.CrossrefMedlineGoogle Scholar10 Tsuruda T, Kato J, Kitamura K, Kuwasako K, Imamura T, Koiwaya Y, Tsuji T, Kangawa K, Eto T. Adrenomedullin: a possible autocrine or paracrine inhibitor of hypertrophy of cardiomyocytes. Hypertension. 1998; 31: 505–510.CrossrefMedlineGoogle Scholar11 Chun TH, Itoh H, Ogawa Y, Tamura N, Takaya K, Igaki T, Yamashita J, Doi K, Inoue M, Masatsugu K, Korenaga R, Ando J, Nakao K. Shear stress augments expression of C-type natriuretic peptide and adrenomedullin. Hypertension. 1997; 29: 1296–1302.CrossrefMedlineGoogle Scholar12 Tsuruda T, Kato J, Kitamura K, Imamura T, Koiwaya Y, Kangawa K, Komuro I, Yazaki Y, Eto T. Enhanced adrenomedullin production by mechanical stretching in cultured rat cardiomyocytes. Hypertension. 2000; 35: 1210–1214.CrossrefMedlineGoogle Scholar13 Nagaya N, Satoh T, Nishikimi T, Uematsu M, Furuichi S, Sakamaki F, Oya H, Kyotani S, Nakanishi N, Goto Y, Masuda Y, Miyatake K, Kangawa K. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation. 2000; 101: 498–503.CrossrefMedlineGoogle Scholar14 Hayakawa H, Hirata Y, Kakoki M, Suzuki Y, Nishimatsu H, Nagata D, Suzuki E, Kikuchi K, Nagano T, Kangawa K, Matsuo H, Sugimoto T, Omata M. Role of nitric oxide-cGMP pathway in adrenomedullin-induced vasodilation in the rat. Hypertension. 1999; 33: 689–693.CrossrefMedlineGoogle Scholar15 Szokodi I, Kinnunen P, Tavi P, Weckstrom M, Toth M, Ruskoaho H. Evidence for cAMP-independent mechanisms mediating the effects of adrenomedullin, a new inotropic peptide. Circulation. 1998; 97: 1062–1070.CrossrefMedlineGoogle Scholar16 Champion HC, Santiago JA, Murphy WA, Coy DH, Kadowitz PJ. Adrenomedullin-(22-52) antagonizes vasodilator responses to CGRP but not adrenomedullin in the cat. Am J Physiol. 1997; 272: R234–R242.MedlineGoogle Scholar17 Entzeroth M, Doods HN, Wieland HA, Wienen W. Adrenomedullin mediates vasodilation via CGRP1 receptors. Life Sci. 1995; 56: PL19–PL25.MedlineGoogle Scholar18 Kato J, Kitamura K, Kangawa K, Eto T. Receptors for adrenomedullin in human vascular endothelial cells. Eur J Pharmacol. 1995; 289: 383–385.CrossrefMedlineGoogle Scholar19 Tsuruda T, Kato J, Kitamura K, Kawamoto M, Kuwasako K, Imamura T, Koiwaya Y, Tsuji T, Kangawa K, Eto T. An autocrine or a paracrine role of adrenomedullin in modulating cardiac fibroblast growth. Cardiovasc Res. 1999; 43: 958–967.CrossrefMedlineGoogle Scholar20 Michibata H, Mukoyama M, Tanaka I, Suga S, Nakagawa M, Ishibashi R, Goto M, Akaji K, Fujiwara Y, Kiso Y, Nakao K. Autocrine/paracrine role of adrenomedullin in cultured endothelial and mesangial cells. Kidney Int. 1998; 53: 979–985.CrossrefMedlineGoogle Scholar21 Kato H, Shichiri M, Marumo F, Hirata Y. Adrenomedullin as an autocrine/paracrine apoptosis survival factor for rat endothelial cells. Endocrinology. 1997; 138: 2615–2620.CrossrefMedlineGoogle Scholar22 Nishimatsu H, Hirata Y, Shindo T, Kurihara H, Kakoki M, Nagata D, Hayakawa H, Satonaka H, Sata M, Tojo A, Suzuki E, Kangawa K, Matsuo H, Kitamura T, Nagai R. Role of endogenous adrenomedullin in the regulation of vascular tone and ischemic renal injury: studies on transgenic/knockout mice of adrenomedullin gene. Circ Res. 2002; 90: 657–663.LinkGoogle Scholar23 Shindo T, Kurihara H, Maemura K, Kurihara Y, Kuwaki T, Izumida T, Minamino N, Ju KH, Morita H, Oh-hashi Y, Kumada M, Kangawa K, Nagai R, Yazaki Y. Hypotension and resistance to lipopolysaccharide-induced shock in transgenic mice overexpressing adrenomedullin in their vasculature. Circulation. 2000; 101: 2309–2316.CrossrefMedlineGoogle Scholar24 Caron KM, Smithies O. Extreme hydrops fetalis and cardiovascular abnormalities in mice lacking a functional adrenomedullin gene. Proc Natl Acad Sci U S A. 2001; 98: 615–619.CrossrefMedlineGoogle Scholar25 Shindo T, Kurihara Y, Nishimatsu H, Moriyama N, Kakoki M, Wang Y, Imai Y, Ebihara A, Kuwaki T, Ju KH, Minamino N, Kangawa K, Ishikawa T, Fukuda M, Akimoto Y, Kawakami H, Imai T, Morita H, Yazaki Y, Nagai R, Hirata Y, Kurihara H. Vascular abnormalities and elevated blood pressure in mice lacking adrenomedullin gene. Circulation. 2001; 104: 1964–1971.CrossrefMedlineGoogle Scholar26 McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 1998; 393: 333–339.CrossrefMedlineGoogle Scholar27 Kuwasako K, Kitamura K, Ito K, Uemura T, Yanagita Y, Kato J, Sakata T, Eto T. The seven amino acids of human RAMP2 (86-92) and RAMP3 (59-65) are critical for agonist binding to human adrenomedullin receptors. J Biol Chem. 2001; 276: 49459–49465.CrossrefMedlineGoogle Scholar28 Lisy O, Jougasaki M, Schirger JA, Chen HH, Barclay PT, Burnett JCJr. Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin. Am J Physiol. 1998; 275: F410–F414.MedlineGoogle Scholar29 Rademaker MT, Charles CJ, Cooper GJ, Coy DH, Espiner EA, Lewis LK, Nicholls MG, Richards AM. Combined endopeptidase inhibition and adrenomedullin in sheep with experimental heart failure. Hypertension. 2002; 39: 93–98.CrossrefMedlineGoogle Scholar30 Oehler MK, Norbury C, Hague S, Rees MC, Bicknell R. Adrenomedullin inhibits hypoxic cell death by upregulation of Bcl-2 in endometrial cancer cells: a possible promotion mechanism for tumor growth. Oncogene. 2001; 20: 2937–2945.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Burger A, Stojkovic S, Diedrich A, Wojta J, Demyanets S and Pezawas T (2021) Cardiac biomarkers for risk stratification of arrhythmic death in patients with heart failure and reduced ejection fraction, British Journal of Biomedical Science, 10.1080/09674845.2021.1883257, 78:4, (195-200), Online publication date: 2-Oct-2021. Beygui F, Wild P, Zeller T, Germain M, Castagné R, Lackner K, Münzel T, Montalescot G, Mitchell G, Verwoert G, Tarasov K, Trégouët D, Cambien F, Blankenberg S and Tiret L (2014) Adrenomedullin and Arterial Stiffness, Circulation: Cardiovascular Genetics, 7:5, (634-641), Online publication date: 1-Oct-2014. Manuela C, Laura S, Benedetta S, Raffaele C, Alessandro V, Chiara C, Tommaso P, Daniela G and Silvia D (2014) Adrenomedullin and intermedin gene transcription is increased in leukocytes of patients with chronic heart failure at different stages of the disease, Peptides, 10.1016/j.peptides.2014.01.028, 55, (13-16), Online publication date: 1-May-2014. Hayashi M, Tojo A, Shimosawa T and Fujita T (2013) The Role of Adrenomedullin in the Renal NADPH Oxidase and (Pro)renin in Diabetic Mice, Journal of Diabetes Research, 10.1155/2013/134395, 2013, (1-8), . Pedowska-Włoszek J, Kostrubiec M, Kurnicka K, Ciurzynski M, Palczewski P and Pruszczyk P (2013) Midregional proadrenomedullin (MR-proADM) in the risk stratification of patients with acute pulmonary embolism, Thrombosis Research, 10.1016/j.thromres.2013.08.008, 132:5, (506-510), Online publication date: 1-Nov-2013. Fan D, Takawale A, Lee J and Kassiri Z (2012) Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease, Fibrogenesis & Tissue Repair, 10.1186/1755-1536-5-15, 5:1, Online publication date: 1-Dec-2012. Ahmad T, Fiuzat M, Felker G and O'Connor C (2012) Novel biomarkers in chronic heart failure, Nature Reviews Cardiology, 10.1038/nrcardio.2012.37, 9:6, (347-359), Online publication date: 1-Jun-2012. von Haehling S, Filippatos G, Papassotiriou J, Cicoira M, Jankowska E, Doehner W, Rozentryt P, Vassanelli C, Struck J, Banasiak W, Ponikowski P, Kremastinos D, Bergmann A, Morgenthaler N and Anker S (2010) Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure, European Journal of Heart Failure, 10.1093/eurjhf/hfq031, 12:5, (484-491), Online publication date: 1-May-2010. Takei Y, Ogoshi M, Wong M and Nobata S (2010) Molecular and Functional Evolution of the Adrenomedullin Family in Vertebrates: What Do Fish Studies Tell Us? The calcitonin gene-related peptide family, 10.1007/978-90-481-2909-6_1, (1-21), . Pan C, Zhang J, Yu F, Teng X, Cao C, Wu W, Tang C and Qi Y (2010) Adrenomedullin ameliorates the development of atherosclerosis in apoE−/− mice, Peptides, 10.1016/j.peptides.2010.03.005, 31:6, (1150-1158), Online publication date: 1-Jun-2010. Pan C, Jin S, Cao C, Zhao J, Zhang J, Wang X, Tang C and Qi Y (2007) The myocardial response to adrenomedullin involves increased cAMP generation as well as augmented Akt phosphorylation, Peptides, 10.1016/j.peptides.2007.01.011, 28:4, (900-909), Online publication date: 1-Apr-2007. Pan C, Jiang W, Wu S, Zhao J, Pang Y, Tang C and Qi Y (2006) Potentiated response to adrenomedullin in myocardia and aortas in spontaneously hypertensive rat, Basic Research in Cardiology, 10.1007/s00395-005-0583-y, 101:3, (193-203), Online publication date: 1-May-2006. Chen L, Kis B, Hashimoto H, Busija D, Takei Y, Yamashita H and Ueta Y (2006) Adrenomedullin 2 protects rat cerebral endothelial cells from oxidative damage in vitro, Brain Research, 10.1016/j.brainres.2006.02.128, 1086:1, (42-49), Online publication date: 1-May-2006. Geny B, Ellero B, Chakfe N, Kretz J, Brandenberger G and Piquard F (2006) Cardiac diastolic dysfunction in renal-transplant recipients is associated with increased circulating Adrenomedullin, Clinical Transplantation, 10.1111/j.1399-0012.2005.00486.x, 20:3, (330-335), Online publication date: 1-May-2006. Kuo M, Kuo H, Chiu Y, Chang J, Guh J, Lai Y and Chen H (2005) Decreased synthesis of glomerular adrenomedullin in patients with IgA nephropathy, Journal of Laboratory and Clinical Medicine, 10.1016/j.lab.2005.02.001, 145:5, (233-238), Online publication date: 1-May-2005. Al-Ayadhi L (2005) Neurohormonal changes in medical students during academic stress, Annals of Saudi Medicine, 10.5144/0256-4947.2005.36, 25:1, (36-40), Online publication date: 1-Jan-2005. Pan C, Jiang W, Zhong G, Zhao J, Pang Y, Tang C and Qi Y (2005) Hypertension induced by nitric oxide synthase inhibitor increases responsiveness of ventricular myocardium and aorta of rat tissue to adrenomedullin stimulation in vitro, Life Sciences, 10.1016/j.lfs.2005.04.082, 78:4, (398-405), Online publication date: 1-Dec-2005. Ribatti D, Nico B, Spinazzi R, Vacca A and Nussdorfer G (2005) The role of adrenomedullin in angiogenesis, Peptides, 10.1016/j.peptides.2005.02.017, 26:9, (1670-1675), Online publication date: 1-Sep-2005. Pan C, Qi Y, Wu S, Jiang W, Li G and Tang C (2004) The role of adrenomedullin and its receptor system in cardiovascular calcification of rat induced by Vitamin D3 plus nicotine, Peptides, 10.1016/j.peptides.2004.02.020, 25:4, (601-608), Online publication date: 1-Apr-2004. Jiang W, Yang J, Wang S, Pan C, Qi Y, Zhao J and Tang C (2004) Effects of adrenomedullin on aldosterone-induced cell proliferation in rat cardiac fibroblasts, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 10.1016/j.bbadis.2004.08.001, 1690:3, (265-275), Online publication date: 1-Nov-2004. Pan C, Qi Y, Wang S, Zhao J, Bu D, Li G and Tang C (2004) Alterations of adrenomedullin and its receptor system components in calcified vascular smooth muscle cells, Regulatory Peptides, 10.1016/j.regpep.2004.02.020, 120:1-3, (77-83), Online publication date: 1-Aug-2004. Yang J, Jiang W, Pan C, Qi Y, Wu Q, Pang Y and Tang C (2004) Effects of adrenomedullin on cell proliferation in rat adventitia induced by lysophosphatidic acid, Regulatory Peptides, 10.1016/j.regpep.2004.04.005, 121:1-3, (49-56), Online publication date: 1-Sep-2004. Jiang W, Yang J, Pan C, Qi Y, Pang Y and Tang C (2004) Effects of adrenomedullin on cell proliferation in rat adventitia induced by aldosterone, Journal of Hypertension, 10.1097/00004872-200410000-00018, 22:10, (1953-1961), Online publication date: 1-Oct-2004. Qi Y, Wang S, Zhang B, Bu D, Shu T and Du J (2003) Changes in amount of ADM mRNA and RAMP2 mRNA in calcified vascular smooth muscle cells, Peptides, 10.1016/S0196-9781(03)00036-6, 24:2, (287-294), Online publication date: 1-Feb-2003. KURIHARA H, SHINDO T, OH-HASHI Y, KURIHARA Y and KUWAKI T (2003) Targeted Disruption of Adrenomedullin and αCGRP Genes Reveals Their Distinct Biological Roles, Hypertension Research, 10.1291/hypres.26.S105, 26:Suppl, (S105-S108), . Westphal M, Stubbe H, Bone H, Daudel F, Vocke S, Van Aken H and Booke M (2002) Hemodynamic effects of exogenous adrenomedullin in healthy and endotoxemic sheep, Biochemical and Biophysical Research Communications, 10.1016/S0006-291X(02)00821-5, 296:1, (134-138), Online publication date: 1-Aug-2002. April 5, 2002Vol 90, Issue 6 Advertisement Article InformationMetrics https://doi.org/10.1161/01.RES.0000015462.11528.28PMID: 11934826 Originally publishedApril 5, 2002 KeywordsadrenomedullintransgenicknockoutautocrineparacrinePDF download Advertisement
Referência(s)